<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8264">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01954004</url>
  </required_header>
  <id_info>
    <org_study_id>PROCEDE-1000</org_study_id>
    <nct_id>NCT01954004</nct_id>
  </id_info>
  <brief_title>Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients</brief_title>
  <official_title>An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myriad Genetic Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myriad Genetic Laboratories, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry is intended to evaluate the impact of genomic test results towards selecting a
      first-line therapy option for newly diagnosed localized prostate cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>4 Months</target_duration>
  <primary_outcome>
    <measure>Percentage change from the recorded PRE-Prolaris® test treatment option versus the ACTUAL treatment option implemented following results of genomic risk assessment testing (Prolaris®).</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from the recorded PRE-Prolaris® test treatment option versus the POST-Prolaris® test treatment plan following review of the genomic test results (prior to patient consultation)</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from the recorded PRE-Prolaris® test treatment option versus the POST-Prolaris® test treatment plan following consultation with the patient.</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>• The mean change in the physician's likelihood of recommending non-interventional therapy (watchful waiting or active surveillance) post-genomic testing compared to pre-genomic testing.</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Recently diagnosed treatment-naïve patients with early stage localized prostate cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed (≤6 months), untreated patients with histologically proven
             adenocarcinoma of the prostate that have the following characteristics.

          -  Clinically localized (no evidence on clinical or imaging studies of advanced
             disease).

          -  No hormonal therapy including LHRH (luteinizing hormone-releasing hormone) agonist or
             antagonist, anti-androgen, estrogens or exogenous androgens, when applicable.

          -  Sufficient amount of tissue remains from biopsy to perform genomic testing.

        Exclusion Criteria:

          -  Patients with a known history of hypogonadism
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abebe Haregewoin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Myriad Genetic Laboratories, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen Rushton</last_name>
    <email>krushton@myriad.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 26, 2013</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
